Debrief: What This Screen Supports and What It Does Not

The cell-based model explains what actually happens on a cell surface during initiation, amplification, and propagation, and it explains fibrin formation, stabilization by factor XIIIa, and fibrinolytic balance. PT, aPTT, TT, fibrinogen, and anti-Xa are separate in-vitro reagent challenges layered on top of that physiology; each one asks a specific, limited question about citrated plasma in a cuvette, not a direct readout of what is happening inside a patient's vessel.

The guided case supports an isolated aPTT prolongation pointing broadly toward intrinsic/contact factors, an anticoagulant effect, or an inhibitor, with a measurable heparin-calibrated anti-Xa result that is compatible with, but does not prove, a heparin explanation. It does not support a specific diagnosis, a confirmed heparin contamination call, or a confirmed factor deficiency from the screening pattern alone.

A normal PT and aPTT do not exclude every bleeding disorder. Factor XIII deficiency will not prolong either test, because neither reagent system challenges XIIIa-mediated cross-linking, and disorders of primary hemostasis, such as platelet function defects, are not detected by a plasma clot-based screen at all. Every reagent, analyzer, interval, ISI, and anti-Xa calibration used at the bench needs local verification; the active method, reagent lot, and locally verified intervals for a real specimen are always a local laboratory decision.

Separate what the method measured from what the result may mean, every time, and hold off on naming a cause until the pattern, the specimen, and local policy all agree.